Blueprint Medicines Corp [BPMC] stock is trading at $94.86, up 3.85%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BPMC shares have gain 2.82% over the last week, with a monthly amount glided 3.60%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Blueprint Medicines Corp [NASDAQ: BPMC] stock has seen the most recent analyst activity on October 27, 2023, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $85 for it. Previously, Needham reaffirmed its Buy rating on August 21, 2023, and elevated its price target to $66. On July 31, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $82 on the stock. SVB Securities downgraded its rating to a Underperform and decreased its price target to $43 on June 05, 2023. Wells Fargo upgraded its rating to a Equal Weight but $41 remained the price target by the analyst firm on January 03, 2023. Needham started tracking with a Buy rating for this stock on December 14, 2022, and assigned it a price target of $60. In a note dated November 02, 2022, Oppenheimer downgraded an Perform rating on this stock.
Blueprint Medicines Corp [BPMC] stock has fluctuated between $43.89 and $101.00 over the past year. Currently, Wall Street analysts expect the stock to reach $94 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $94.86 at the most recent close of the market. An investor can expect a potential drop of -0.91% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
Blueprint Medicines Corp [NASDAQ:BPMC] reported sales of 249.38M for the trailing twelve months, which represents a growth of 85.55%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.99%, Pretax Profit Margin comes in at -2.03%, and Net Profit Margin reading is -2.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -1.92 and Total Capital is -0.6. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of5.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 91.67 points at the first support level, and at 88.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 97.23, and for the 2nd resistance point, it is at 99.59.
Blueprint Medicines Corp [BPMC] reported earnings per share of -$1.82 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$2.04/share, meaning a difference of $0.22 and a surprise factor of 10.80%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$2.2 per share as compared to estimates of -$2.37 per share, a difference of $0.17 representing a surprise of 7.20%.
Ratios To Look Out For
For context, Blueprint Medicines Corp’s Current Ratio is 3.76. Further, the Quick Ratio stands at 3.66, while the Cash Ratio is 0.33. Considering the valuation of this stock, the price to sales ratio is 23.29, the price to book ratio is 44.41.
Transactions by insiders
Recent insider trading involved Landsittel Michael, CHIEF FINANCIAL OFFICER, that happened on Mar 28 ’24 when 5000.0 shares were sold. Director, Albers Jeffrey W. completed a deal on Mar 20 ’24 to sell 25073.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Landsittel Michael sold 13734.0 shares on Mar 15 ’24.
